Cargando…

Clinical outcomes of intravenous levetiracetam treatment in patients with renal impairment

Intravenous levetiracetam has been approved for use as an antiepileptic drug, as well as in cases of status epilepticus. There are few reports that detail the clinical data and outcomes associated with this antiepileptic drug, particularly in patients with renal impairment. This was a retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Lapmag, Anyamanee, Lertsinudom, Sunee, Chaiyakam, Aporanee, Sawanyawisuth, Kittisak, Tiamkao, Somsak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176471/
https://www.ncbi.nlm.nih.gov/pubmed/30344963
http://dx.doi.org/10.4081/ni.2018.7469
_version_ 1783361709732265984
author Lapmag, Anyamanee
Lertsinudom, Sunee
Chaiyakam, Aporanee
Sawanyawisuth, Kittisak
Tiamkao, Somsak
author_facet Lapmag, Anyamanee
Lertsinudom, Sunee
Chaiyakam, Aporanee
Sawanyawisuth, Kittisak
Tiamkao, Somsak
author_sort Lapmag, Anyamanee
collection PubMed
description Intravenous levetiracetam has been approved for use as an antiepileptic drug, as well as in cases of status epilepticus. There are few reports that detail the clinical data and outcomes associated with this antiepileptic drug, particularly in patients with renal impairment. This was a retrospective analytical study conducted at Khon Kaen University’s Srinagarind Hospital in Thailand. The study period was between January 1, 2010 and December 31, 2014. The inclusion criteria were that patents were over 15 years old, had renal impairment, and had received intravenous levetiracetam treatment. The main clinical outcomes were seizure control and mortality. Clinical outcomes were compared between those with and without status epilepticus. Mortality of patients with status epilepticus were compared in terms of seizure control and order of intravenous levetiracetam treatment. During the study period, there were 247 patients who met the study criteria. The average age of the patients was 58 years with nearly equal sex distribution. Of those, 90 patients (36.4%) had GRFs of less than 15 mL/min/1.73 m(2) and 60 patients (24.3%) received intravenous LEVE due to status epilepticus. The seizure control rates in the status epilepticus and non-status epilepticus groups were 36.7% and 88.7%, respectively (P<0.001). The mortality rate did not differ significantly between the two groups (33.3% vs 27.8%; P=0.418). There was no significant overall difference in mortality rate between seizure-controlled and seizure-uncontrolled patients in the status epilepticus group. In the convulsive status epilepticus group, variations in terms of treatment order of intravenous levetiracetam and seizure control resulted in no significant difference in mortality rates (P=0.311). No major side effects were detected in any patients after the intravenous levetiracetam treatment. In conclusion, intravenous levetiracetam treatment was effective and safe in patients with renal impairment.
format Online
Article
Text
id pubmed-6176471
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher PAGEPress Publications, Pavia, Italy
record_format MEDLINE/PubMed
spelling pubmed-61764712018-10-19 Clinical outcomes of intravenous levetiracetam treatment in patients with renal impairment Lapmag, Anyamanee Lertsinudom, Sunee Chaiyakam, Aporanee Sawanyawisuth, Kittisak Tiamkao, Somsak Neurol Int Article Intravenous levetiracetam has been approved for use as an antiepileptic drug, as well as in cases of status epilepticus. There are few reports that detail the clinical data and outcomes associated with this antiepileptic drug, particularly in patients with renal impairment. This was a retrospective analytical study conducted at Khon Kaen University’s Srinagarind Hospital in Thailand. The study period was between January 1, 2010 and December 31, 2014. The inclusion criteria were that patents were over 15 years old, had renal impairment, and had received intravenous levetiracetam treatment. The main clinical outcomes were seizure control and mortality. Clinical outcomes were compared between those with and without status epilepticus. Mortality of patients with status epilepticus were compared in terms of seizure control and order of intravenous levetiracetam treatment. During the study period, there were 247 patients who met the study criteria. The average age of the patients was 58 years with nearly equal sex distribution. Of those, 90 patients (36.4%) had GRFs of less than 15 mL/min/1.73 m(2) and 60 patients (24.3%) received intravenous LEVE due to status epilepticus. The seizure control rates in the status epilepticus and non-status epilepticus groups were 36.7% and 88.7%, respectively (P<0.001). The mortality rate did not differ significantly between the two groups (33.3% vs 27.8%; P=0.418). There was no significant overall difference in mortality rate between seizure-controlled and seizure-uncontrolled patients in the status epilepticus group. In the convulsive status epilepticus group, variations in terms of treatment order of intravenous levetiracetam and seizure control resulted in no significant difference in mortality rates (P=0.311). No major side effects were detected in any patients after the intravenous levetiracetam treatment. In conclusion, intravenous levetiracetam treatment was effective and safe in patients with renal impairment. PAGEPress Publications, Pavia, Italy 2018-09-25 /pmc/articles/PMC6176471/ /pubmed/30344963 http://dx.doi.org/10.4081/ni.2018.7469 Text en ©Copyright A. Lapmag et al., 2018 http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Lapmag, Anyamanee
Lertsinudom, Sunee
Chaiyakam, Aporanee
Sawanyawisuth, Kittisak
Tiamkao, Somsak
Clinical outcomes of intravenous levetiracetam treatment in patients with renal impairment
title Clinical outcomes of intravenous levetiracetam treatment in patients with renal impairment
title_full Clinical outcomes of intravenous levetiracetam treatment in patients with renal impairment
title_fullStr Clinical outcomes of intravenous levetiracetam treatment in patients with renal impairment
title_full_unstemmed Clinical outcomes of intravenous levetiracetam treatment in patients with renal impairment
title_short Clinical outcomes of intravenous levetiracetam treatment in patients with renal impairment
title_sort clinical outcomes of intravenous levetiracetam treatment in patients with renal impairment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176471/
https://www.ncbi.nlm.nih.gov/pubmed/30344963
http://dx.doi.org/10.4081/ni.2018.7469
work_keys_str_mv AT lapmaganyamanee clinicaloutcomesofintravenouslevetiracetamtreatmentinpatientswithrenalimpairment
AT lertsinudomsunee clinicaloutcomesofintravenouslevetiracetamtreatmentinpatientswithrenalimpairment
AT chaiyakamaporanee clinicaloutcomesofintravenouslevetiracetamtreatmentinpatientswithrenalimpairment
AT sawanyawisuthkittisak clinicaloutcomesofintravenouslevetiracetamtreatmentinpatientswithrenalimpairment
AT tiamkaosomsak clinicaloutcomesofintravenouslevetiracetamtreatmentinpatientswithrenalimpairment
AT clinicaloutcomesofintravenouslevetiracetamtreatmentinpatientswithrenalimpairment